Impact of COVID-19 pandemic on the clinical activities related to arrhythmias and electrophysiology in Italy: results of a survey promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing)
- PMID: 32889687
- PMCID: PMC7474489
- DOI: 10.1007/s11739-020-02487-w
Impact of COVID-19 pandemic on the clinical activities related to arrhythmias and electrophysiology in Italy: results of a survey promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing)
Abstract
COVID-19 outbreak had a major impact on the organization of care in Italy, and a survey to evaluate provision of for arrhythmia during COVID-19 outbreak (March-April 2020) was launched. A total of 104 physicians from 84 Italian arrhythmia centres took part in the survey. The vast majority of participating centres (95.2%) reported a significant reduction in the number of elective pacemaker implantations during the outbreak period compared to the corresponding two months of year 2019 (50.0% of centres reported a reduction of > 50%). Similarly, 92.9% of participating centres reported a significant reduction in the number of implantable cardioverter-defibrillator (ICD) implantations for primary prevention, and 72.6% a significant reduction of ICD implantations for secondary prevention (> 50% in 65.5 and 44.0% of the centres, respectively). The majority of participating centres (77.4%) reported a significant reduction in the number of elective ablations (> 50% in 65.5% of the centres). Also the interventional procedures performed in an emergency setting, as well as acute management of atrial fibrillation had a marked reduction, thus leading to the conclusion that the impact of COVID-19 was disrupting the entire organization of health care, with a massive impact on the activities and procedures related to arrhythmia management in Italy.
Keywords: Ablation; Arrhythmia; Atrial fibrillation; COVID-19; Emergency; Implantable cardioverter defibrillators; Pacemakers; Remote monitoring.
Conflict of interest statement
GB: small speaker fee from Medtronic, Boston, Biotronik, Boehringer Ingelheim and Bayer. PP: small speaker fee from Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Medtronic. Novartis and personal fees from Proctorship agreement with Abbott, Medtronic, Biotronik, and Boston Scientific. MB: small speaker fee from Boston Scientific, Abbott, Boehringer Ingelheim and Bayer. ML: modest speaker fee from Bayer, Boehringer Ingelheim, Boston Scientific, LivaNova, Medtronic, and Pfizer. RPR: small speaker fees by Boston e Biotronik; advisory board modest fees by Dompé. RDP: lecture fees from Biosense Webster and Biotronik. No conflict of interest reported by the other authors.
Figures
References
-
- Bedford J, Enria D, Giesecke J, Heymann DL, Ihekweazu C, Kobinger G, Lane HC, Memish Z, Oh MD, Sall AA, Schuchat A, Ungchusak K, Wieler LH, WHO Strategic and Technical Advisory Group for Infectious Hazards COVID-19: towards controlling of a pandemic. Lancet. 2020;395:1015–1018. doi: 10.1016/S0140-6736(20)30673-5. - DOI - PMC - PubMed
-
- COVID-19 ITALIA (2020) Data from Italian Civil Protection Department. https://opendatadpc.maps.arcgis.com/apps/opsdashboard/in. Accessed 27 June 2020. - PubMed
-
- De Rosa S, Spaccarotella C, Basso C, Calabrò MP, Curcio A, Filardi PP, Mancone M, Mercuro G, Muscoli S, Nodari S, Pedrinelli R, Sinagra G, Indolfi C, Società Italiana di Cardiologia and the CCU Academy investigators group Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era. Eur Heart J. 2020;41:2083–2088. - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
